Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using 18F-FLT PET

[1]  K. Krohn,et al.  The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells. , 2012, Nuclear medicine and biology.

[2]  Valerie A Longo,et al.  Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. , 2013, Molecular imaging.

[3]  P. Szlosarek,et al.  Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Barré,et al.  Automated Radiosynthesis of [18F]ML-10, a PET Radiotracer Dedicated to Apoptosis Imaging, on a TRACERLab FX-FN Module , 2013, Molecular Imaging and Biology.

[5]  S. Larson,et al.  Positron emission tomography in thyroid cancer management. , 2002, Seminars in roentgenology.

[6]  J. Gribben,et al.  Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis , 2012, Cell Death and Disease.

[7]  J. Sherley,et al.  Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.

[8]  S. Reske,et al.  PTEN mutation: many birds with one stone in tumorigenesis. , 2008, Anticancer research.

[9]  F. Izzo,et al.  Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Wangpaichitr,et al.  Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. , 2010, Current molecular medicine.

[11]  Y. Nishiyama,et al.  Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers , 2011, Molecular Imaging and Biology.

[12]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Bieling,et al.  Accelerated breast MRI for breast cancer screening. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Giovanni Lucignani,et al.  Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  N. Tamaki,et al.  Monitoring tumor proliferative response to radiotherapy using 18F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67 , 2013, Annals of Nuclear Medicine.

[16]  D. Nguyen,et al.  The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. , 2010, Biochemical and biophysical research communications.

[17]  S. Dry,et al.  3′‐deoxy‐3′‐[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma , 2012, Cancer.

[18]  J. Dixon,et al.  PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.

[19]  A. Schetter,et al.  The Induction of microRNA-16 in Colon Cancer Cells by Protein Arginine Deiminase Inhibition Causes a p53-Dependent Cell Cycle Arrest , 2013, PloS one.

[20]  Frank Y. S. Chuang,et al.  Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. , 2009, Cancer research.

[21]  J. Wolchok,et al.  Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma , 2013, Investigational New Drugs.

[22]  F. Mottaghy,et al.  Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition. , 2012, American journal of nuclear medicine and molecular imaging.

[23]  T. Crook,et al.  Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma , 2013, Cell Death and Disease.

[24]  H. Hoekstra,et al.  [18F]FLT-PET in oncology: current status and opportunities , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  S. Larson,et al.  Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest 18F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma , 2012, The Journal of Nuclear Medicine.

[26]  M. Wangpaichitr,et al.  Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase , 2012, British Journal of Cancer.

[27]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Curley,et al.  Incidence and distribution of argininosuccinate synthetase deficiency in human cancers , 2004, Cancer.

[29]  J. Schwartz,et al.  The role of nucleoside/nucleotide transport and metabolism in the uptake and retention of 3'-fluoro-3'-deoxythymidine in human B-lymphoblast cells. , 2011, Nuclear medicine and biology.

[30]  Hong Wu,et al.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. , 2003, Cancer cell.

[31]  G. Antoni,et al.  18F-ML-10, a PET Tracer for Apoptosis: First Human Study , 2011, The Journal of Nuclear Medicine.

[32]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  M. Wuest,et al.  Biodistribution and Uptake of 3′-Deoxy-3′-Fluorothymidine in ENT1-Knockout Mice and in an ENT1-Knockdown Tumor Model , 2010, The Journal of Nuclear Medicine.

[34]  L. Old,et al.  Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase , 2011, British Journal of Cancer.

[35]  Lawrence H Schwartz,et al.  18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  N. Savaraj,et al.  Pegylated arginine deiminase: a novel anticancer enzyme agent , 2006, Expert opinion on investigational drugs.

[37]  G. Knoll,et al.  Single-photon emission computed tomography , 1983, Proceedings of the IEEE.

[38]  S. Hirohashi,et al.  Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma , 2010, Molecular Cancer Therapeutics.

[39]  S. Eriksson,et al.  Investigation on Cell Proliferation with a New Antibody against Thymidine Kinase 1 , 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[40]  K. Krohn,et al.  Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake. , 2004, Nuclear medicine and biology.